TG Therapeutics, Inc. - Common Stock (TGTX)
Frequently Asked Questions About TG Therapeutics, Inc. - Common Stock (TGTX)
Does TG Therapeutics have partnerships or collaborations?
Yes, TG Therapeutics has engaged in various partnerships and collaborations with academic institutions and industry players to advance its research and development efforts. These collaborations often focus on innovative approaches to treatment and can accelerate the development process by leveraging combined expertise and resources.
How does TG Therapeutics support the patient community?
TG Therapeutics is committed to supporting the patient community through educational initiatives, advocacy, and access programs. The company works collaboratively with organizations, healthcare providers, and patients to raise awareness about B-cell malignancies and autoimmune diseases, ensuring that patients have access to the necessary resources and information related to their treatment options.
How is TG Therapeutics funded?
TG Therapeutics is funded through a combination of public and private financing, including venture capital investments, public offerings, and strategic partnerships. The revenue generated from these activities supports the company's research and development programs, allowing them to advance their pipeline of therapies.
Is TG Therapeutics publicly traded?
Yes, TG Therapeutics is publicly traded on the NASDAQ under the ticker symbol TGTX. The company went public to raise capital for its development programs and increase its visibility within the investment community, allowing investors to participate in its growth.
What are the lead product candidates of TG Therapeutics?
TG Therapeutics has several lead product candidates including TG-1101 (ublituximab), a novel glycoengineered anti-CD20 monoclonal antibody, and TG-1501, a novel selective inhibitor of PI3K delta. These candidates primarily target various forms of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, aiming to provide more effective treatment options.
What are the main therapeutic areas for TG Therapeutics?
TG Therapeutics primarily focuses on hematologic malignancies, including various types of blood cancers such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, as well as autoimmune diseases. By concentrating on these areas, the company aims to provide targeted and effective treatments for patients with significant healthcare needs.
What clinical trials is TG Therapeutics currently conducting?
TG Therapeutics is currently conducting several clinical trials to evaluate the safety and efficacy of its product candidates, including ublituximab and TG-1501. These trials are pivotal in determining the potential of these therapies to address B-cell malignancies and are ongoing across multiple sites to gather comprehensive clinical data.
What does TG Therapeutics, Inc. do?
TG Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of hematologic malignancies and autoimmune diseases. The company primarily targets B-cell malignancies and utilizes its proprietary platforms to develop monoclonal antibodies and small molecule therapies. TG Therapeutics aims to address unmet medical needs and improve patient outcomes through its research and development efforts.
What has been the FDA's response to TG Therapeutics' filings?
The FDA has been supportive of TG Therapeutics' progress by granting designations such as Breakthrough Therapy Designation for their lead candidate, ublituximab. This reflects the agency’s recognition of the product's potential to address significant unmet medical needs, indicating a favorable view of its ongoing development and supporting the company's efforts towards regulatory approvals.
What is TG Therapeutics' approach to research and development?
TG Therapeutics adopts a innovative and patient-centered approach to research and development by leveraging its proprietary technologies to design and develop therapies that target specific disease mechanisms. The company prioritizes scientific excellence and collaboration to ensure its therapies are both effective and safe, enabling it to achieve meaningful clinical advancements.
What is TG Therapeutics' mission?
TG Therapeutics' mission is to develop innovative medicines that enhance the quality of life for patients suffering from debilitating diseases. The company aims to serve unmet medical needs by delivering effective therapies that transform treatment paradigms, ultimately leading to better health outcomes for patients.
What is the company’s vision for the future?
TG Therapeutics envisions a future where patients with hematologic malignancies and autoimmune diseases have access to more effective and safer treatment options. The company's strategic plan includes expanding its pipeline, advancing its clinical trials, and working closely with regulatory agencies to bring innovative therapies to market that can transform patient care.
What is the significance of the Breakthrough Therapy Designation?
The Breakthrough Therapy Designation is a status granted by the U.S. Food and Drug Administration (FDA) to expedite the development and review of drugs that treat serious conditions and fulfill an unmet medical need. For TG Therapeutics, obtaining this designation for ublituximab signifies the agency's recognition of the potential benefits that their therapy may provide in treating chronic lymphocytic leukemia.
What is ublituximab?
Ublituximab (TG-1101) is a novel glycoengineered monoclonal antibody that targets CD20, a protein expressed on the surface of B-cells. It is being developed for the treatment of various B-cell malignancies, and is designed to enhance the efficacy of the immune response against cancer cells while minimizing side effects compared to traditional therapies.
What stage are TG Therapeutics' product candidates currently in?
Many of TG Therapeutics' product candidates are in various stages of clinical development. The company's lead candidate, ublituximab, has completed several clinical trials and has been granted Breakthrough Therapy Designation by the FDA for the treatment of CLL. The company actively updates its pipeline status as it progresses through trials towards potential regulatory submissions.
When was TG Therapeutics founded?
TG Therapeutics was founded in 2012. Since its inception, the company has focused on harnessing advanced biopharmaceutical technologies to deliver innovative therapies, building a strong pipeline that targets serious diseases, particularly within hematology and autoimmune fields.
Where is TG Therapeutics, Inc. headquartered?
TG Therapeutics, Inc. is headquartered in New York City, New York. The company's central office functions as the hub for its research, development, and administrative activities, facilitating collaboration among its teams as they work on advancing innovative therapies in the biotech sector.
Who are the key executives at TG Therapeutics?
The executive team at TG Therapeutics includes experienced professionals in the biotechnology and pharmaceutical industries. Key executives include the CEO and President, who has extensive experience in drug development, as well as individuals overseeing various departments including research, operations, and regulatory affairs, all committed to advancing the company's mission.
What is the current price of TG Therapeutics, Inc. - Common Stock?
The current price of TG Therapeutics, Inc. - Common Stock is 39.82
When was TG Therapeutics, Inc. - Common Stock last traded?
The last trade of TG Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of TG Therapeutics, Inc. - Common Stock?
The market capitalization of TG Therapeutics, Inc. - Common Stock is 6.15B
How many shares of TG Therapeutics, Inc. - Common Stock are outstanding?
TG Therapeutics, Inc. - Common Stock has 154.42M shares outstanding.